Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
111In-panitumumab for Nodal Staging in Head and Neck Cancer
NCT05901545Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2023
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 111In-panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Incidence of adverse events grade 2 or higher at 15 days. Started Aug 2023; status: recruiting.
02
Drugs
111In-panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05901545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901545.